FIELD: medicine.
SUBSTANCE: hypoosmotic ophthalmic means contains riboflavin mononucleotide, hydroxypropylmethylcellulose, tris-(hydroxymethyl)-methylamine, nipagin and purified water. The ingredients are used in the declared ratio.
EFFECT: use of the invention provides stroma hydration, necessary increase in the cornea thickness by means of the hypoosmotic properties of the solution, optimal intrastromal concentration of riboflavin, reduced instillations due to stable precorneal film formed by hydroxypropylmethylcellulose introduction.
1 ex
Title | Year | Author | Number |
---|---|---|---|
HYPO-OSMOTIC OPHTHALMIC AGENT FOR ULTRAVIOLET CROSS-LINKING OF THIN CORNEAS | 2024 |
|
RU2841327C1 |
OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 |
|
RU2646452C1 |
OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 |
|
RU2560669C1 |
OPHTHALMIC CROSS-LINKING AGENT-2 | 2012 |
|
RU2475248C1 |
CROSS-LINKING OPHTHALMIC AGENT | 2009 |
|
RU2412707C1 |
METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 |
|
RU2682494C1 |
OPHTHALMOLOGICAL MEANS FOR CORNEAL INJURIES AND DISEASES DIAGNOSTICS | 2016 |
|
RU2633083C1 |
METHOD OF CORNEAL GRAFT PREPARATION FOR LAYER-BY-LAYER KERATOPLASTY | 2019 |
|
RU2723135C1 |
COMBINED METHOD FOR THE TREATMENT OF CORNEAL DISEASES WITH THE USE OF KERATOPLASTY AND CROSS-LINKING | 2017 |
|
RU2676434C1 |
METHOD OF TREATING EPITHELIAL-ENDOTHELIAL CORNEAL DYSTROPHY | 2019 |
|
RU2703361C1 |
Authors
Dates
2017-09-25—Published
2016-11-07—Filed